Safety of Nasal Influenza Immunisation in Children With Asthma
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been
approved by a number of licensing boards and is given by a spray into the nose. In the United
Kingdom (UK), the vaccine has been demonstrated to be highly effective against influenza
infection. Further, despite concerns that LAIV can cause wheezing in children under age 2
years, the previous SNIFFLE studies have demonstrated it to be safe in children over 2 years
with mild-moderate asthma.
The objective of this multicentre study is to further assess the safety of intranasal LAIV in
children with asthma and recurrent wheeze, including those with severe symptoms.